GET DAILY SIGNALSExploring Natural Alternatives International (NAII) and Its Position in the Nutritional Supplements Space
Key Takeaways
- NAII is Natural Alternatives International, Inc., a U.S.-based formulator, manufacturer, and marketer of nutritional supplements, founded in 1980 and headquartered in Carlsbad, California.
- The company operates through two reportable segments: Private-Label Contract Manufacturing and Patent and Trademark Licensing.
- A key differentiator is its patent estate around the ingredient beta-alanine, sold under the CarnoSyn®, SR CarnoSyn®, and TriBsyn™ trademarks.
- NAII serves customers across direct-sales, direct-to-consumer e-commerce, and retail channels, with manufacturing operations in California and Switzerland.
- The company has reported net losses in recent fiscal years, which is an important consideration for investors evaluating its financial profile.
Introduction
Natural Alternatives International, Inc. (NAII) operates in the health and nutrition sector in a way that may not stand out to most investors at first glance. Yet its work supports many well-known supplement brands through contract manufacturing and ingredient licensing rather than direct consumer sales under its own name. This behind-the-scenes role gives the company exposure to the broader dietary supplement industry.
Company Overview
Founded in 1980 and reorganized as a Delaware corporation in 1989, NAII is headquartered in Carlsbad, California. Its main U.S. manufacturing sites are in Vista and Carlsbad, California. In 1999 the company added a wholly owned subsidiary, Natural Alternatives International Europe S.A., in Manno, Switzerland, to extend its international reach.
NAII reports through two segments. Private-Label Contract Manufacturing accounts for most revenue and involves producing vitamins, minerals, herbal, and other nutritional supplements for brands that sell them under their own labels. The Patent and Trademark Licensing segment focuses on intellectual property tied to beta-alanine, an amino acid used in sports nutrition products. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Model and Revenue Sources
The company builds its model around long-term partnerships with customers. Services extend beyond manufacturing to include customized formulation, clinical study support, regulatory review, international registration, packaging design, product testing, and marketing assistance. Private-label clients reach consumers through direct-sales, e-commerce, and retail channels. Products come in capsules, tablets, chewable wafers, and powders.
On the licensing side, revenue comes from direct sales of beta-alanine raw material plus royalties and license fees linked to the CarnoSyn®, SR CarnoSyn®, and TriBsyn™ trademarks. These patents create a competitive edge that supports both contract work and third-party supply deals.
Market Position and Key Markets
NAII competes in the contract-manufacturing and nutritional-ingredients space, serving U.S. and international customers. The Swiss operation handles encapsulation, tableting, powder production, packaging, quality control, warehousing, and distribution for Europe. Certifications such as Good Manufacturing Practices (GMPs) and Therapeutic Goods Administration (TGA) compliance help support exports to regulated markets.
Why Investors Follow NAII
Investors track NAII for its exposure to growing dietary supplement and sports-nutrition markets without relying on a single consumer brand. The beta-alanine patent portfolio offers a science-backed ingredient business that can generate recurring royalty and supply income. Diversified manufacturing and international operations allow service across channels and regions. From what I see, revenue growth in recent periods stands alongside net losses and a notable debt load on the balance sheet. Long-term prospects depend on converting partnerships and intellectual property into consistent profitability.
Risks and Important Considerations
Several factors warrant attention. The supplement industry is competitive, with many manufacturers and suppliers pursuing the same clients. Customer concentration poses another risk, as revenue can hinge on a limited number of large private-label accounts. Regulatory oversight from the FDA and international bodies can influence manufacturing, labeling, and ingredient approvals. Recent net losses and debt levels add financial considerations, while reliance on beta-alanine patents introduces exposure to potential expirations, litigation, or competing ingredients.
Using Tickeron Tools in Research
When reviewing companies like NAII, I find Tickeron’s AI-powered platforms helpful for screening and signal generation. They allow quick comparison across technical indicators, fundamentals, and industry patterns without replacing deeper fundamental analysis.
Conclusion
Natural Alternatives International holds a distinct place as a contract manufacturer and ingredient licensor in the nutritional supplement sector. Its mix of private-label work and a proprietary beta-alanine patent estate differentiates it from many peers, while U.S. and Swiss facilities provide international reach. For investors, NAII represents participation in long-term health and sports-nutrition growth alongside competitive, regulatory, and financial considerations that shape its operations.
AI Trading Bots
In my own workflow I have found Tickeron’s AI Trading Bots useful for testing automated strategies on smaller-cap names. The platform lets users explore virtual agents that align with specific risk parameters, which can complement manual review of companies like NAII when evaluating entry or exit ideas over time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NAII's Stochastic Oscillator slumps into oversold zone
The Stochastic Oscillator for NAII moved into oversold territory on November 11, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for NAII just turned positive on October 20, 2026. Looking at past instances where NAII's MACD turned positive, the stock continued to rise in 30 of 47 cases over the following month. The odds of a continued upward trend are 64%.
Following a +5.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAII advanced for three days, in 123 of 185 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
NAII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NAII as a result. In 85 of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAII declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for NAII entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.139) is normal, around the industry mean (6.914). P/E Ratio (-0.324) is within average values for comparable stocks, (7.137). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.083) is also within normal values, averaging (5.003).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. NAII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of customized nutritional supplements
Industry FoodMajorDiversified
Advertisement